Despite multimodal treatment, the prognosis of high-grade gliomas is grim. As tumor growth is critically dependent on new blood vessel formation, antiangiogenic treatment approaches offer an innovative treatment strategy. Bevacizumab, a humanized monoclonal antibody, has been in the spotlight of antiangiogenic approaches for several years. Currently, MRI including contrast-enhanced T1-weighted and T2/fluid-attenuated inversion recovery (FLAIR) images is routinely used to evaluate antiangiogenic treatment response (Response Assessment in Neuro-Oncology criteria). However, by restoring the blood -brain barrier, bevacizumab may reduce T1 contrast enhancement and T2/FLAIR hyperintensity, thereby obscuring the imaging-based detection of progression. The aim of this review is to highlight the recent role of imaging biomarkers from MR and PET imaging on measurement of disease progression and treatment effectiveness in antiangiogenic therapies. Based on the reviewed studies, multimodal imaging combining standard MRI with new physiological MRI techniques and metabolic PET imaging, in particular amino acid tracers, may have the ability to detect antiangiogenic drug susceptibility or resistance prior to morphological changes. As advances occur in the development of therapies that target specific biochemical or molecular pathways and alter tumor physiology in potentially predictable ways, the validation of physiological and metabolic imaging biomarkers will become increasingly important in the near future.
High-grade gliomas (HGGs) are highly aggressive primary brain tumors. Despite multimodal treatment, patients with HGGs, in particular glioblastoma multiforme (GBM), have an unfavorable prognosis. 1 After first tumor recurrence, the median survival ranges between only 3 and 9 months. 2, 3 As tumor growth is critically dependent on new blood vessel formation, antiangiogenic treatment approaches offer an attractive treatment strategy. 4 The coincidence of pathological neovascularization and high expression levels of vascular endothelial growth factor (VEGF) led to the conception that VEGF may be a suitable target for antiangiogenic treatment. 5 Bevacizumab, a humanized monoclonal antibody targeting VEGF-A, has been in the spotlight of antiangiogenic therapies for several years. Recently, bevacizumab was investigated in 2 large-scale, randomized, phase III trials (AVAglio and RTOG-0825) 6, 7 for GBM first-line treatment and demonstrated improved progression-free survival (PFS) in both trials and maintained quality of life in the AVAglio trial. Both studies failed to prolong overall survival (OS). Results from clinical trials in recurrent HGG (rHGG) reported response rates of 28% -57%, improved 6-month PFS rates of 29% -50%, decreased peritumoral edema, and improved quality of life. 3,8 -11 A recently published phase II randomized trial of first recurrent GBM (rGBM) showed an improvement of the combination of bevacizumab and lomustine in comparison with bevacizumab or lomustine alone (BELOB study) 12 and led to the adaptation of the running European Organisation for Research and Treatment of Cancer 26101 study to a 2-arm randomized phase III registration trial.
Currently, contrast-enhanced MRI is routinely used to evaluate antiangiogenic treatment response. 9, 10 Since contrast enhancement reflects vascular permeability, therapeutic strategies blocking VEGF and, therefore, reducing tumor vascular permeability may have a significant impact on the heavily MR-based tumor response criteria, formulated initially by Macdonald and colleagues 13 and later by the Response Assessment in Neuro-Oncology (RANO) working group.
14 Therefore, the validity of traditional imaging assessment of PFS has been questioned, and innovative imaging strategies are warranted.
Therefore, we provide an in-depth comprehensive analysis of current studies of baseline, early-, and late-change imaging biomarkers derived from structural and advanced MR and metabolic PET imaging following antiangiogenic treatment in HGG. In addition, we discuss key issues in imaging biomarker validation and qualification.
Standard MRI

Outcome and Response Evaluation
Currently, standard MRI, including contrast-enhanced T1-weighted images (CE-T1WI), is routinely used to evaluate antiangiogenic treatment response in clinical trials and daily neuro-oncological practice.
14 Contrast enhancement was generally considered to show vital tumor tissue, since it reflects the abnormal blood -brain barrier (BBB) permeability of the notoriously abundant dysfunctional tumor vessels of HGG. However, contrast enhancement may significantly decrease following BBB normalization by antiangiogenic agents, and this effect can occur as early as 24 -48 h after initiation of therapy. 9 -11 This observation is not necessarily indicative of a true antitumor effect and has, therefore, been termed a "pseudo-response." 14 Furthermore, highly infiltrative HGG tumor burden is not always associated with abnormal BBB permeability ("nonenhancing tumor"). As these tumors still yield a signal increase on T2-weighted and fluid-attenuated inversion recovery (FLAIR) images, these imaging characteristics were introduced in the revised RANO response criteria 14 together with the term "pseudo-response," 14 which indicates a more than 50% reduction of contrast enhancement but is not associated with a significant decrease of nonenhancing tumor. However, there remain unresolved issues yet. The RANO criteria do not yet quantify the degree of T2/FLAIR changes to define tumor progression. Furthermore, tumor-related edema or ischemia, radiationinduced changes, demyelination, and infection can result in hyperintense T2/FLAIR signals, which makes it difficult to distinguish nonneoplastic signal alterations from nonenhancing tumor. Further, progression patterns under bevacizumab treatment may vary considerably among patients with HGGs, complicating the evaluation of treatment response. 15 
T1-Weighted Imaging
Each MRI protocol for brain tumor imaging includes pre-and postcontrast T1WI. The current tumor response criteria are based on 2D measurements of tumor cross-sectional areas on CE-T1WI rather than a 3D volume calculation. It has been shown that conventional 2D evaluation is comparable to 3D volume measurement. 16, 17 In contrast, other studies have revealed that automatic segmentation is more sensitive for detecting tumor progression than is subjective MRI assessment. 18 Despite the limitations of standard MRI, several studies have demonstrated that treatment response criteria, 11,19 -23 pretreatment CE-T1WI tumor volumes, 24, 25 early CE-T1WI tumor volume changes, and residual CE-T1WI volumes in the early follow-up MRI scans might serve as predictors for both PFS and OS (Table 1) . 17, 24, 25 In contrast, baseline or early posttreatment T2/FLAIR volumes and T2/FLAIR volume changes were not significantly associated with improved outcome (Table 1) . 17, 24, 25 These results indicate that the antiangiogenic effect, reflected by a reduction in contrast enhancement, might be associated with real antitumor effect and with better prognosis for the patient.
In addition, bevacizumab treatment induces response-related tumor calcification depicted as hyperintense areas on precontrast T1WI and associated with better prognosis (see also diffusion-restriction and tumor calcification below). 26, 27 
T2/FLAIR Sequences
Despite the fact that changes in T2/FLAIR volume upon initial bevacizumab treatment are not a predictor for PFS and OS, the pretreatment ratio of FLAIR/contrast-enhancing volume might be predictive for both, 24 being unique features accessible before starting the bevacizumab therapy. The authors of this work argue that these results may indicate that nonenhancing tumor-related changes at recurrence are related to a better outcome. However, T2/FLAIR hyperintensities observed in HGGs delineate not only nonenhancing tumor but also tumorassociated edema, treatment-related changes (eg, perioperative ischemia, infection/inflammation, postradiation demyelination, leukencephalopathy). 28 After initiation of bevacizumab therapy, there is frequently an impressive reduction of edema leading to a decreased edema/tumor volume ratio and reduced necrotic tumor areas. 18, 29, 30 Since tumor infiltration is associated with less edema under bevacizumab therapy, T2/FLAIR imaging may more appropriately show tumor infiltration. However, the high signal in T2/FLAIR images is physically based on a prolongation of the T2-relaxation time compared with normal tissue, which is less pronounced during bevacizumab treatment compared with pretreatment. 31 This leads to a specific change of the T2/FLAIR signal of the tumor, 30 resulting in a low reliability of T2/FLAIR evaluation with a high interobserver variability. 32 One approach to better detect nonenhancing tumors is to subtract T2-relaxation-time maps during bevacizumab treatment from the map of best response (first scan after treatment started), so that even subtle changes may be detectable. 31, 33 Artzi et al 34 recently reported another approach identifying nonenhancing FLAIR areas as tumor using multiple MRI parameters based on mean diffusivity and fractional anisotropy, cerebral blood volume (CBV), and flow maps. An increase of the percentage of the tumor-infiltrative volume detected at weeks 8 and 16 but not at baseline was associated with poorer PFS (Table 1) .
Advanced MRI
Diffusion-Weighted Imaging
Diffusion-weighted imaging (DWI) was introduced in tumor diagnosis as a method indicating cell density of a tumor. The underlying rationale came from stroke imaging: narrowed extracellular space decreases the diffusion of water molecules Hutterer et al.: Multimodal response assessment of antiangiogenic therapies in HGG ) ¼ contrast-enhancing tumor on CE-T1WI without necrosis volume. in the extracellular space. Restricted diffusion is quantitatively measured by the apparent diffusion coefficient (ADC) value, which is lower in highly cellular tumors and higher in edema and necrosis. 35 Gupta et al 36 reported that decreased ADC might even precede contrast enhancement in progressive HGGs. However, DWI signal changes can be ambiguous and DWI restriction is also found in other pathologies (eg, abscesses, hematomas). In the context of bevacizumab treatment, strokelike diffusion restriction (ie, decreased ADC values) appears shortly (4 -8 wk) after treatment initiation and remains stable during treatment course (Fig. 1A) . 26, 37, 38 Histological evaluation of these MRI lesions revealed extensive calcified atypical eosinophilic coagulative necrosis, hyalinization of blood vessels, reactive astrocytosis/gliosis, and increased cellularity, possibly due to infiltration of lymphocytes and monocytes, a phenomenon closely related to the biology of HGG. 26, 27, 38, 39 DWI restriction, especially in combination with tumor calcification on precontrast T1WI, was in most cases related to improved outcome and prolonged response (Tables 1  and 2) . 46, 58 Therefore, this phenomenon might be used as an early imaging biomarker of treatment response.
ADC values may be able to identify patients with rHGG having a higher chance to benefit from bevacizumab early in therapy or before starting treatment. 40, 41 ADC histograms from areas of enhancing tumor were fitted to a mixed model involving a double Gaussian distribution and produced evidence that the mean ADC from the lower curve (ADC L ) was associated with longer PFS and OS during bevacizumab treatment, but not during other chemotherapies. 40 -44 Furthermore, the change in the skewed profile of the ADC histogram 45 and a number of MRI parameters derived from functional diffusion maps (fDMs) (traditional vs graded fDMs; linear vs nonlinear fDMs; cell invasion, motility, and proliferation level estimate image maps) 46 - 48 may be predictive for treatment response early in the course of antiangiogenic therapy (Table 2 ). In contrast, a decrease in ADC upon treatment in the enhancing and nonenhancing tumor volume appears to be associated with tumor progression, possibly indicating viable and denser tumor tissue. 49 Yamasaki and colleagues 50 demonstrated that a high DWI b-value (b ¼ 4000) can differentiate between a pseudo-response and real tumor progression during bevacizumab treatment. The b-value identifies the measurement's sensitivity to diffusion and determines the strength and duration of the diffusion gradients.
Apart from the described biological ambiguities of ADC changes, methodical concerns such as standardization of measurement parameters, artifact minimization, and improvement of spatial resolution still remain unresolved.
Perfusion-Weighted Imaging
Perfusion-weighted imaging (PWI) as a biomarker for response to antiangiogenic drugs has generated significant interest, as it seems to reflect the direct biological response to bevacizumab.
Dynamic susceptibility contrast (DSC) PWI allows generation of maps of relative CBV (rCBV), relative cerebral blood flow (rCBF), and mean transit time. Mean and median CBV and BBB permeability were significantly reduced after a single dose of bevacizumab, indicating normalization of the abnormal tumor vasculature. 51, 52 Recently it was shown that in rHGG patients, pre-and posttreatment rCBV maps could predict significantly longer OS (Table 2) . 53 Sawlani et al 54 demonstrated that the percentage change in hyperperfusion volume (the fraction of contrast-enhancing tumor with an rCBV above a predetermined threshold of 1.0) was significantly correlated with PFS in rGBM patients. Component analysis of DSC voxels with perfusion characteristics of both arteries and veins (arteriovenous overlap) revealed an improved median OS in bevacizumabtreated rGBM patients with a decrease in arteriovenous overlap volume (Table 2) . 55 Interestingly, in an animal model, serial DSC MR acquisition using the iron oxide contrast agent ferumoxytol was more sensitive in detecting true rCBV and tumor progression than gadodiamide, and this was independent of gadodiamide preload or corticosteroid treatment. 56, 57 The main methodical limitation of DSC MRI in monitoring HGGs is attributed to the presence of the BBB, since gadoliniumcontaining contrast agent outside the vasculature enhances T1 relaxation of tissue water. This T1 effect may counteract the susceptibility induced signal loss in DSC images leading to an underestimation of CBV and thereby reducing the diagnostic accuracy to detect progression of HGGs. Despite intensive efforts, there is still no generally accepted solution for this methodical problem. 58 In this regard, metabolic active tumor volumes were significantly larger in O-(2- ; P , .001), the spatial overlap of both imaging parameters was poor (congruence, 11.0%), and mean distance between the local hot spots differed considerably. 59 Dynamic contrast-enhanced (DCE) PWI allows measurement of K trans , a value determining the rate at which the contrast agent moves from the vasculature to the extracellular space and therefore representing a marker for BBB permeability. In an animal model, a single dose of bevacizumab significantly decreased tumor vasculature permeability. 57 Sorensen et al 60 studied patients with rGBM treated with cediranib, an inhibitor of the VEGF receptor tyrosine kinases, and calculated a "vascular normalization index" by combining K trans , microvessel volume, and circulating collagen IV measured 1 day after treatment initiation; the authors found this to be predictive of PFS and OS. Again, there are unresolved methodical issues of DCE PWI that reduce the diagnostic accuracy. Parameter calculations of DCE images are based on complex pharmacokinetic compartment models that allow only an approximation of the biological conditions. Other drawbacks of DCE MRI are the low signal change, which results in low signal to noise in the calculated parameter maps, and the large variety of methodical approaches lacking standardization.
susceptibility to artifacts, especially in frontotemporal areas near the skull base, 63 and the low signal/noise ratio of metabolite signals. Therefore, enough vital tumor volume without predominant necrosis is needed to discriminate tumor spectra, particularly in rGBM. 64 Only a few studies investigated MRS during antiangiogenic treatment. Kim and colleagues 63 found an increase in NAA/ Cho only 28 days after starting cediranib treatment, suggesting that this antiangiogenic drug has an effect on cellular metabolism that is temporally separated from its immediate ) from a male patient with recurrent anaplastic astrocytoma who developed a long-lasting response under bevacizumab treatment (RANO criteria first follow-up scan after 4 wk: no contrast enhancement, significant reduction in T2/FLAIR signal abnormality). The patient developed early (wk 4) hyperintense tumor calcification on precontrast T1WI associated with an extended hypovascularized DWI restriction (low rCBV, high ADC values), indicating calcified coagulative tumor necrosis, blood vessel hyalinization, reactive astrocytosis/gliosis, and increased cellularity due to inflammatory cells. (B) Baseline and first follow-up MRI and 18 F-FET/ 18 F-FLT scans from a female patient with recurrent glioblastoma. According to RANO criteria, the patient presented with a partial response due to significant decrease of contrast enhancement and T2/FLAIR signal hyperintensity. At baseline, 18 F-FET PET revealed a focal high tracer uptake consistent with the contrast enhancement on MRI, but also a high ratio of nonenhancing metabolically active tumor. The follow-up scan showed a decrease of the focal tracer uptake; the BTV, however, remained stable (metabolic nonresponder). Importantly, 18 F-FLT PET demonstrated only tracer uptake dependent on elevated BBB permeability, thereby correlating with MRI contrast enhancement at baseline and the follow-up scan. DCE-T1WI ¼ delta T1 map presenting the real contrast enhancement; T2WI ¼ T2-weighted imaging; CBV ¼ relative cerebral blood volume (DSC PWI); FET ¼ Traditional fDMs (5) Early-BEV 6 w scan Vol. ADC FLAIR decrease < 13cc (median) (77 rGBM pts) N/A P 5 .003 (HR 1.98)
Vol. ADC CE-T1WI decrease < 2cc (median) N/A P 5 .001 (HR 2.08)
Graded fDMs (6) Early-BEV 6 w scan Vol. ADC FLAIR decrease < 12cc (median) N/A P 5 .002 (HR 2.01)
Vol. ADC CE-T1WI decrease < 1.5cc (median) N/A P < .001 (HR 2.68)
Higher mode (7) of ADC
CE-T1WI
N/A P < .001 (HR 3.26)
Linear fDMs (8) Early-BEV 6 w scan %V ADC CE-T1WI(9) < median (linear fDMs) (70 rGBM pts) P ¼ .106
%V ADC FLAIR(9) < median (linear fDMs) P 5 .002
Nonlinear fDMs (8) Early-BEV 6 w scan %V ADC CE-T1WI(9) < median (pre-to-post nonlinear fDMs) P ¼ .067
%V ADC CE-T1WI(9) < median (post-to-pre nonlinear fDMs) P 5 .017
%V ADC FLAIR(9) < median (pre-to-post nonlinear fDMs) P < .001
%V ADC FLAIR(9) < median (post-to-pre nonlinear fDMs) P 5 .017 (11) mean Rho ¼ group average value of mean proliferation rate; max Rho ¼ group average value of the maximum proliferation rate; mean migration ¼ group average value of mean cell migration rate. (12) DHPV ¼ percent change in hyperperfusion volume, defined as the percentage of voxels within the contrast-enhancing tumor volume of interest in which rCBV values were greater than a predetermined threshold. (13) Independent component analysis separated vasculature into arterial and venous components; AVOL ¼ voxels with perfusion characteristics of both arteries and veins (arteriovenous overlap), which is significantly higher than in normal vasculature (P , .001). antivascular effects. In line with this hypothesis, a relative NAA/ Cho increase after this 28-day time window appears to be predictive of 6-month survival in rGBM patients treated with cediranib or bevacizumab in combination with cytotoxic chemotherapy. 63, 65 However, these studies revealed phenomena during treatment and failed to provide predictive parameters before the start of treatment.
More specific changes in tumor metabolism can be evaluated using phosphorus ( 31 P) spectra, which measure metabolites of membrane phospholipids, the intracellular pH, and products of oxidative phosphorylation; all of these are involved in tumor metabolism. Preliminary data suggest that 31 P-MRS may be predictive for bevacizumab treatment response. In 31 P spectra, the choline peak is differentiated into phosphocholine (PCho) and glycerophosphocholine (GPC). In 32 rGBM patients, PCho/ GPC before antiangiogenic treatment was only elevated in patients with short survival time. In 14 patients who were monitored over an extended period, PCho/GPC decreased significantly during antiangiogenic treatment and increased during tumor progression. 66 
PET Imaging
Currently, standard MRI is the most important diagnostic tool for assessing brain tumors because of its excellent soft-tissue contrast and multiplanar reconstruction capabilities. 67 However, structural MRI has key limitations in the identification of nonenhancing tumor parts and in the assessment of treatment response (pseudo-progression, pseudo-response) or tumor recurrence.
14 Metabolic imaging using radiolabeled tracers for PET constitutes an innovative class of tumor imaging and may overcome some of the disadvantages of MRI due to its more accurate estimation of size and extension of the metabolically active tumor. 68, 69 At present, the amino acid tracers [ 11 C]-methionine ( 11 C-MET), 18 F-FET, and L-3,4-dihydroxy-6-18 F-fluoro-phenylalanine ( 18 F-FDOPA) are the most commonly used for examining metabolic activity of brain tumors. 68 -71 Amino acid tracers are substrates to the large neutral amino acid transport system that is highly expressed in tumor and vascular cells of glial brain tumors. 71, 72 Elevated tracer uptake, presented as a high standard uptake value (SUV), significantly correlates with tumor cell density and proliferation rate as well as microvascular density. 73 Importantly, the amino acid uptake occurs largely independently of regional tumor perfusion and BBB permeability, identifying nonenhancing tumor areas better than standard MRI alone. 74 -76 Moreover, a decrease in amino acid metabolism appears to be an early sign of chemotherapy response in low-and high-grade gliomas. 77, 78 Therefore, amino acid PET in conjunction with structural MRI may be more reliable in assessing treatment response of antiangiogenic treatments than MRI alone. 74 -76 Recently, 2 studies demonstrated that 18 F-FET PET was able to identify additional nonenhancing metabolically highly active tumor lesions with elevated local CBV that did not respond to anti-VEGF bevacizumab treatment and cannot be derived from MRI assessment based upon RANO criteria alone (Table 3) . 74, 76 In addition, MRI and 18 F-FET PET response assessment was discordant in 36% -40% of patients with significant earlier detection of treatment failure by 18 F-FET PET (Fig. 1B) , resulting in a median treatment benefit of between 9.0 and 10.5 weeks. 74, 76 At the time of the first follow-up scan, 4 -8 weeks after the start of treatment, a decrease of more than 45% of the metabolically active biological tumor volume (BTV) differentiated metabolic responders (PFS ≥6 mo) from nonresponders (PFS ,6 mo) with almost 3 times longer median PFS and significantly longer OS for responders (Table 3) . 74, 76 A number of 18 F-FET PET studies have shown that the evaluation of the 18 F-FET tracer kinetics may provide relevant diagnostic information, especially for noninvasive tumor grading. 79, 80 With respect to bevacizumab treatment, a prolonged time to peak (TTP) at baseline had a high predictive value, meaning that a slow flooding of the tumor with 18 F-FET tracer correlated to an improved outcome. Furthermore, a reduction in the mean tumor-to-brain ratio (TBR mean ) of more than 17% at early follow-up and a certain arrangement of TTP and defined tracer kinetic pattern at baseline and follow-up discriminated responders from nonresponders with a sensitivity of 100% and a specificity of 75% (Table 3) . 76 In line with 18 F-FET PET, metabolic imaging by 18 F-FDOPA PET measuring absolute BTVs at baseline, 2 weeks, and 6 weeks, as well as their changes between these time points, was predictive for PFS and OS with highest hazard ratios for absolute BTV at 2 weeks and BTV changes at 2 and 6 weeks (hazard ratios, 9.05, 2.94, and 4.02, respectively; Table 3 ). 23 Furthermore, comparing responders by PET and MRI RANO criteria (6 wk scan), 8/24 cases (33%) were diagnosed discrepant and 18 F-FDOPA predicted treatment failure significantly earlier than MRI, leading to a median time benefit of 7.2 weeks (range, 2-20 wk) for earlier detection. 23 The evaluation of voxelwise changes in 18 F-FDOPA uptake referring to parametric response maps (PRMs) revealed that a voxelwise increase in 18 F-FDOPA uptake in areas of pretreatment contrast enhancement on MRI stratified patients for 3-month PFS and 6-month OS. A decrease in tracer uptake was associated with longer PFS and OS, and vice versa. Finally, the volume fraction of increased 18 F-FDOPA uptake between the first 2 posttreatment time points discriminated long-and short-term PFS and OS (Table 3) .
18 F]-labeled thymidine analogue that showed a close correlation between uptake and tumor cell proliferation. 82 Two clinical trials examined the predictive value of 18 F-FLT PET in patients with rHGG treated with bevacizumab in combination with irinotecan. 23, 83 A reduction of 18 F-FLT uptake of more than 25% at 6 weeks served as the optimal threshold for response and discriminated responders (47%) from nonresponders (53%) with longer median OS. Metabolic responders survived 3 times longer in comparison with nonresponders (Table 3) . 83 18 F-FLT uptake changes at 2 and 6 weeks were more predictive for PFS and OS than MRI responses. 23, 83 Multivariate analysis identified a lack of 18 F-FLT reduction at 6 weeks as the strongest independent predictor for PFS and OS. 23 However, the major limitation of this tracer is that a BBB breakdown seems to be a prerequisite for 18 F-FLT uptake (Fig. 1B) , and even HGGs with high proliferation index may be 18 F-FLT negative if they lack contrast enhancement on MRI. 84 In rHGG receiving antiangiogenic bevacizumab treatment, baseline SUV max and TBR max deriving from 18 F-fluoro-deoxyglucose ( 18 F-FDG) PET, a radiolabeled glucose analogue, were
Hutterer et al.: Multimodal response assessment of antiangiogenic therapies in HGG powerful independent predictors of both PFS and OS and were also prognostic for treatment response (Table 3) . 85 However, 18 F-FDG uptake is problematic in the evaluation of HGG, as the normal brain has a high glucose metabolism background.
PET is ideally suited for the visualization of metabolic processes and specific molecules in the brain and tumor. However, this method lacks the spatial resolution of anatomic information offered by MRI. Therefore, the combination of PET and MRI by hybrid PET/MRI technology is highly complementary, and in future, simultaneous PET/MRI data acquisition will allow the addition of kinetic, functional, and molecular/metabolic information for real-time multiparametric functional imaging.
Image Processing and Data Analysis
The aim of image data analysis in the context of response assessment for HGG is the comparison of pre-and posttreatment data to differentiate responders and nonresponders. Depending on response criteria and imaging modality, a large variety of image processing methods have been developed. Major drawbacks of any advanced MRI technique are the lack of standardized acquisition parameters and of postprocessing algorithms for data evaluation. Further, data need time-consuming postprocessing, unless there is standard and easily applicable software. Consequently, the implementation for clinical routine is work intensive, and the diagnostic value of these MR techniques is difficult to validate, especially between different institutions.
Image Processing for MRI-based Data
To assess treatment response, the volume of the tumor has to be evaluated. Tumor segmentation is a challenging task and can be reached by manual tumor delineation, 86 semi-automatic procedures, 87 and fully automatic algorithms. 88 As manual segmentation is highly dependent on the human operator limiting reliability, semi-automatic approaches should be performed as a minimum. 89 Currently, freely available software like ITK-Snap 45, 74 (performing an active contour procedure) and 3D Slicer 90 (with a graph-cut approach) are frequently applied. Particularly in the field of MRI, established preprocessing like denoising, 18 skull stripping, 29 and intensity normalization 86, 91 are important prior to segmentation.
Having the tumor regions in pre-and posttreatment images delineated, a histogram analysis of the whole tumor volume can characterize tumor growth. 51, 92 Histograms have the advantage that small segmentation errors are negligible. 29 Nevertheless, histograms do not account for the heterogeneous treatment response of GBM.
92
A voxel-by-voxel comparison of pre-and posttreatment MRIs could overcome this drawback. However, the coregistration of all MRI data to a common baseline is mandatory for this approach. Functional diffusion maps based on ADC data, 46, 47 as well as PRMs based on rCBV images, 93 have been established recently as biomarkers for treatment response. It is generally accepted to use an affine transformation model and mutual information as a similarity measure for fDMs and PRMs. However, there is no standard procedure available for image coregistration. Registration approaches, such as MIAMI Fuse and the Functional Magnetic Resonance Imaging of the Brain (FMRIB) Linear Image Registration Tool, 47 lack broad acceptance, and detailed parameters are not yet published.
Furthermore, pre-and posttreatment MRI data suffer from a mixture of linear and nonlinear differences. Reasons for the latter are mainly mass effects of growing tumor. The first approaches to overcome the problem of growing tumors, such as the publicly available GLISTR (glioma image segmentation and registration) approach, 91 adjust the registration to an atlas of healthy volunteers adding a tumor model into the optimization procedure. Other approaches have experimented with the nonlinear B-spline-based FMRIB nonlinear image registration tool of the FMRIB Software Library package with sum-of-squares similarity measure. 47 In the future, more research in this field is warranted.
Image Processing for Combined PET/MRI-based Data
To make use of combined PET/MRI-based data, the tumor region within the PET data has to be delineated, and MRI/PET data have to be coregistered to compare the tumor region in both modalities. An established procedure for tumor delineation in PET is the manual selection of nontumorous regions, such as in the contralateral hemisphere, to determine normal SUV mean . Here, an operator located the tumor by defining a reasonable TBR as a fixed value 94 or by visual inspection. 95 The drawback of this procedure is the operator-dependent selection of the normal tissue region of interest, which might influence the resulting tumor boundary. Several semi-automatic approaches for PET tumor segmentation and the impact of user-dependent parameterization have been studied. 96 Coregistration of MRI/PET data can be done using commercially or freely available tools, such as PMOD, 71 Statistical Parametric Mapping, 97 VINCI, 76 and iPlan. 95 A comprehensive comparison of the different approaches is impossible considering the number of unknown parameters of coregistration and the large variety of tools and solutions.
Conclusions
The search for clinically useful response criteria and imaging biomarkers of treatment response in HGGs is challenging. In our opinion, state-of-the-art imaging in neuro-oncology has to be tightly adapted to the respective treatment situations. Currently, standard antiangiogenic treatment response assessment (RANO criteria) 14 uses strictly anatomic measurements of structural MRI based on contrast-enhancing tumor on T1WI and hyperintense T2/FLAIR changes. Herein, the major problems of the RANO criteria are as follows: (i) contrast enhancement may significantly decrease following BBB normalization, which is not necessarily indicative of a true antitumor effect ("pseudo-response"), leaving HGG tumor burden without abnormal BBB permeability ("nonenhancing tumor"); (ii) T2/ FLAIR signal abnormalities reflect not only metabolically active tumor (solid or infiltrative), but also peritumoral edema (also caused by VEGF-mediated enhanced BBB permeability and typically reduced during anti-VEGF treatment) and treatmentrelated changes (eg, radiation-associated demyelination or leukencephalopathy, perioperative ischemic or inflammatory effects), which makes it difficult to distinguish tumor from Hutterer et Early BEV SUV max, mean change 2 w + 6 w scans n.s. 
Early-BEV Vol( 1 /-) Lack of FLT response 6 w scan P 5 .001 
Early-BEV %Vol(1/2) F-FET uptake, the curve is always ascending with a clear identifiable peak SUV at the end of the dynamic study; type 2 pattern ¼ the maximum peak is reached at a midway point (TTP .20 -45 min) followed by a plateau or a slow descent; type 3 pattern ¼ the peak of the curve occurs at an early time point (TTP ≤20 min) followed by a steep decrease. (6) When 2 of 3 criteria are fulfilled: (1) an increase in TTP of ≥10 min between baseline and follow-up; (2) a TTP of ≥25 min at baseline; and (3) a type 1 or 2 kinetic pattern at follow-up. nonneoplastic signal alterations; (iii) RANO tumor response evaluation is defined by cutoff values based on T1WI contrast enhancement (partial response, decrease .50%; progression, increase ≥25% or new lesion). Corresponding changes on T2/ FLAIR sequences are termed only "significant" or "not significant," without substantiating a defined threshold. A more detailed integration of criteria for T2/FLAIR evaluation-as planned for the next version of the criteria-will not completely clear the problem (see point ii). As discussed later, PET imaging could resolve some of these problems. From our point of view, the RANO criteria should further aim at an improved monitoring of the patients' clinical state, including serial predefined neurological examinations, patient-reported outcome analyses, 98 and, if available, repetitive neurocognitive testing. 6, 7 In our view, antiangiogenic treatment monitoring of HGG patients has routinely to include not only the standard MRI sequences pre-/postcontrast T1WI and T2/FLAIR, but also the widely available DWI, ADC, and DSC PWI. As reviewed in detail, a significant reduction of the contrast-enhancing tumor volume in early MRI scans shortly after start of treatment, but not a decrease in the corresponding T2/FLAIR signal abnormalities, was predictive and/or prognostic for bevacizumab treatment (Table 1) . Furthermore, bevacizumab-induced tumor calcification on precontrast T1WI and hypovascularized DWI restrictions (decreased rCBF/rCBV, elevated ADC values) represented strong imaging biomarkers for improved treatment outcome and prolonged response (Tables 1 and 2 ). Importantly, in GBM patients with or without bevacizumab, nonenhancing DWI-restricted and hypervascularized lesions preceded the development of a new enhancing tumor. 36 Thus, DSC PWI including correction for contrast material leakage (Table 2) should routinely be included.
As presented in detail, additional metabolic PET imaging provides an important and valuable addition to standard MRI. In recent years, especially amino acid PET tracers such as 18 F-FET, 11 C-MET, and (with a smaller foundation in the literature) 18 F-FDOPA were clinically validated for brain tumor diagnosis, treatment planning, and monitoring and have already reached a broad acceptance within the neuro-oncological community, with a wide use in dedicated neuro-oncology centers. The advantages of amino acid PET compared with MRI alone are its possibility (i) to identify both contrast-enhancing and nonenhancing metabolically active high-grade tumor independent from BBB permeability with high sensitivity and specificity, 75 and (ii) to discriminate tumor from nontumorassociated signal abnormalities on T2/FLAIR sequences (eg, peritumoral edema, treatment-related changes). 74, 76 Considering its BBB independence and additional value in the evaluation of the metabolically active tumor volumes and TBRs, we recommend that amino acid PET should be further implemented in neuro-oncology multimodal imaging, especially in the course of antiangiogenic treatment monitoring and as study endpoint. 18 F-FET and 18 F-FDOPA have logistical advantages over 11 C-MET due to the longer half-life of the 18 F label (109 vs 20 min, respectively) and its independence from a local cyclotron. All 3 tracers provide comparable diagnostic information. 18 F-FDOPA, however, has the disadvantage of intensive physiological uptake into the brain basal ganglia, leading to difficult tumor delineation in the situation of adjacent tumor localization (eg, insular, temporal, frontal). Importantly, an 18 F-FLT tracer uptake is, in contrast to amino acid tracers, significantly dependent on tumor BBB permeability and is thus restricted mainly to contrast-enhancing tumor lesions (Fig. 1B) . Therefore, in our view, response assessment of antiangiogenic treatment in HGG based on 18 F-FLT PET has to be interpreted with caution. 84 In addition to its prognostic and predictive value under antiangiogenic therapy, multimodal imaging combining standard and advanced MRI with amino acid PET imaging may have the ability to detect drug susceptibility or resistance prior to morphological changes. Saying this, a more individually tailored medicine is possible, potentially avoiding overtreatment by significantly earlier detection of treatment failure ("pseudoresponse") than with standard MRI alone (Table 3) , 74, 76, 99 resulting in unnecessary side effects and corresponding costs. 100 Furthermore, comparison of the standard RANO criteria with 18 F-FET and 18 F-FDOPA response assessment demonstrated that 33% -40% of MRI responders were nonresponders in amino acid PET, revealing a high value of potentially false-responsive diagnosed patients by MRI criteria alone (Fig. 1B) . 74, 76, 99 Furthermore, the integrated view on combined MRI/PET modality showed at baseline a contrast-enhancing tumor on standard MRI smaller than the median tumor volume (Table 1) and a low mean ADC value of the lower peak (ADC L ; Table 2 ). It also showed that in early MRI/PET follow-up scans (4-8 wk after treatment started), predictive and/or prognostic imaging biomarkers for antiangiogenic treatment were: a significant reduction of the contrast-enhancing tumor volumes (Table 1) , a voxelwise ADC volume change between post-and pretreatment ADC fDMs on standard and advanced MRI (Table 2) , a significant reduction of BTVs, and TBR mean using amino acid PETs (Table 3 ). These observations indicate that patients with a small tumor volume at baseline (eg, after tumor resection of the HGG recurrence) and/or with a favorable treatment response resulting in a small (absolute) residual tumor burden in the early MRI/ PET scans may represent a subgroup of HGG patients who respond significantly better than others to bevacizumab. However, the number of investigated patients is low at this time, and no broadly accepted and prospectively evaluated standard methods for defining metabolic responders have been invented. 74, 76, 99 Therefore, a general recommendation cannot be given, and further prospective data from large populations are necessary.
It is important to process all acquired images adequately (which takes time) and to include the raised information in all relevant procedures. State-of-the-art software tools (though not standardized) should ensure advanced multimodal imaging processing as well as a seamless integration in, for instance, biopsy and radiotherapy planning systems. Interdisciplinary approaches are helpful to reach an optimal integration of all imaging, clinical, and histological information for the sake of the patient.
Unfortunately, the clinical utility of most physiological and metabolic imaging techniques remains unproven at this time, and most of the methods lack standardization. Therefore, welldesigned large prospective studies are required to show that the presented preliminary findings are robust, accurate, and reproducible and to determine whether the relationship with outcome is predictive. As advances occur in the development of Hutterer et al.: Multimodal response assessment of antiangiogenic therapies in HGG therapies that target specific biochemical or molecular pathways and alter tumor physiology in potentially predictable ways, the validation of physiological and metabolic imaging biomarkers in adequately designed trials will become increasingly important in the near future.
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